

# Sean C Dowdy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8182855/publications.pdf>

Version: 2024-02-01

124  
papers

5,747  
citations

66343

42  
h-index

82547

72  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7398  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ten years of live surgical broadcast at Charit�-MAYO conferences (2010�-2019): a systematic evaluation of the surgical outcome. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003173.	2.5	2
2	The association of acute COVID�19 infection with Patient Safety Indicator�12 events in a multisite healthcare system. <i>Journal of Hospital Medicine</i> , 2022, 17, 350-357.	1.4	5
3	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	5.1	35
4	Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 85-91.	2.5	27
5	Deployment of an Interdisciplinary Predictive Analytics Task Force to Inform Hospital Operational Decision-Making During the COVID-19 Pandemic. <i>Mayo Clinic Proceedings</i> , 2021, 96, 690-698.	3.0	9
6	Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program. <i>Gynecologic Oncology</i> , 2021, 160, 835-843.	1.4	5
7	Enhanced Recovery in Gynecologic Surgery. <i>Journal of Gynecologic Surgery</i> , 2021, 37, 122-126.	0.1	0
8	PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 182-189.	1.4	6
9	PARP inhibitor maintenance for primary ovarian cancer � A missed opportunity for precision medicine. <i>Gynecologic Oncology</i> , 2021, 163, 11-13.	1.4	7
10	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. <i>PLoS ONE</i> , 2021, 16, e0245664.	2.5	5
11	Dilution of Molecular�Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 213-219.	7.0	12
12	Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 62-69.	1.4	43
13	Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 278-283.	1.4	6
14	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	1.4	61
15	In Reply. <i>Obstetrics and Gynecology</i> , 2020, 136, 424-425.	2.4	0
16	Vaginal Hysterectomy: Historical Footnote or Viable Route?. <i>Obstetrics and Gynecology</i> , 2020, 136, 426-426.	2.4	1
17	Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 789-796.	2.5	3
18	Guidelines for vulvar and vaginal surgery: Enhanced Recovery After Surgery Society recommendations. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 475-485.	1.3	35

#	ARTICLE	IF	CITATIONS
19	Level I evidence establishes enhanced recovery after surgery as standard of care in gynecologic surgery: now is the time to implement!. American Journal of Obstetrics and Gynecology, 2020, 223, 473-474.	1.3	4
20	Analytics and Prediction Modeling During the COVID-19 Pandemic. Mayo Clinic Proceedings, 2020, 95, S8-S10.	3.0	6
21	Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. International Journal of Gynecological Cancer, 2020, 30, 1738-1747.	2.5	8
22	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. Gynecologic Oncology, 2020, 158, 194-200.	1.4	9
23	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. Gynecologic Oncology, 2020, 158, 201-207.	1.4	5
24	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. Gynecologic Oncology, 2020, 158, 236-243.	1.4	42
25	Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery. Gynecologic Oncology, 2020, 157, 476-481.	1.4	28
26	Use of bowel preparation does not reduce postoperative infectious morbidity following minimally invasive or open hysterectomies. American Journal of Obstetrics and Gynecology, 2020, 223, 231.e1-231.e12.	1.3	7
27	Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?. Gynecologic Oncology, 2020, 156, 568-574.	1.4	15
28	A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecologic Oncology, 2019, 155, 63-68.	1.4	83
29	Improving the rate of surgical normothermia in gynecologic surgery. Gynecologic Oncology, 2019, 154, 590-594.	1.4	5
30	BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Research, 2019, 79, 5920-5929.	0.9	40
31	Prehabilitation: enhancing the Enhanced Recovery after Surgery pathway. International Journal of Gynecological Cancer, 2019, 29, 1233-1234.	2.5	3
32	Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer. Gynecologic Oncology, 2019, 155, 21-26.	1.4	11
33	A pilot study of non-routine events in gynecological surgery: Type, impact, and effect. Gynecologic Oncology, 2019, 152, 298-303.	1.4	11
34	International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. American Journal of Obstetrics and Gynecology, 2019, 221, 237.e1-237.e11.	1.3	93
35	Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendationsâ€™2019 update. International Journal of Gynecological Cancer, 2019, 29, 651-668.	2.5	452
36	Optimizing Preanesthesia Care for the Gynecologic Patient. Obstetrics and Gynecology, 2019, 134, 395-408.	2.4	6

#	ARTICLE	IF	CITATIONS
37	Enhanced Recovery After Surgery and Acute Postoperative Pain Management. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 656-665.	1.1	10
38	Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 286-292.	1.4	26
39	Enhanced Recovery after Minimally Invasive Gynecologic Procedures with Bowel Surgery: A Systematic Review. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 288-298.	0.6	28
40	Cancer susceptibility gene mutations in type I and II endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 20-25.	1.4	32
41	Enhanced recovery after surgery for ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 217-219.	0.3	0
42	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.	2.8	62
43	Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. <i>Gynecologic Oncology</i> , 2018, 148, 480-484.	1.4	60
44	Adjuvant therapy for women with high-risk endometrial carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 268-269.	10.7	9
45	Impact of surgical approach and patient factors on Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey scoring in gynecologic surgery. <i>Gynecologic Oncology</i> , 2018, 148, 28-35.	1.4	7
46	Risk of Surgical Site Infection (SSI) following Colorectal Resection Is Higher in Patients With Disseminated Cancer: An NCCN Member Cohort Study. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 555-562.	1.8	23
47	Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. <i>Gynecologic Oncology</i> , 2018, 149, 291-296.	1.4	12
48	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	1.4	8
49	Enhanced recovery after surgery in gynecologic oncology. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 143-146.	2.3	13
50	Surgical technical evidence review for gynecologic surgery conducted for the Agency for Healthcare Research and Quality Safety Program for Improving Surgical Care and Recovery. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 563.e1-563.e19.	1.3	22
51	Quality indicators in gynecologic oncology. <i>Gynecologic Oncology</i> , 2018, 151, 366-373.	1.4	7
52	Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. <i>Gynecologic Oncology</i> , 2018, 151, 235-242.	1.4	63
53	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	12.8	178
54	Results of a Prospective, Multicenter Initiative Aimed at Developing Opioid-prescribing Guidelines After Surgery. <i>Annals of Surgery</i> , 2018, 268, 457-468.	4.2	173

#	ARTICLE	IF	CITATIONS
55	Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. <i>Gynecologic Oncology</i> , 2017, 145, 21-26.	1.4	58
56	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	7.0	103
57	Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. <i>Gynecologic Oncology</i> , 2017, 146, 187-195.	1.4	24
58	Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial. <i>Obstetrics and Gynecology</i> , 2017, 129, 1139-1139.	2.4	12
59	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2720-2726.	1.5	44
60	In Reply. <i>Obstetrics and Gynecology</i> , 2017, 130, 914-915.	2.4	0
61	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIc endometrial carcinoma at higher risk for nodal disease. <i>Gynecologic Oncology</i> , 2017, 147, 541-548.	1.4	82
62	Reducing infection rates through perioperative glycemic control “how sweet it is. <i>Gynecologic Oncology</i> , 2017, 146, 215-216.	1.4	0
63	Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. <i>Gynecologic Oncology Reports</i> , 2017, 22, 100-104.	0.6	28
64	Improving Surgical Site Infection Rates Through Continuous Quality Improvement. <i>Annals of Surgical Oncology</i> , 2017, 24, 305-307.	1.5	3
65	Abnormal Uterine Bleeding Is Associated With Increased BMP7 Expression in Human Endometrium. <i>Reproductive Sciences</i> , 2017, 24, 671-681.	2.5	14
66	Risk Adjustment of Surgical Site Infection Rates Following Colon Surgery. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
67	Utilization of Minimally Invasive Surgery in Endometrial Cancer Care. <i>Obstetrics and Gynecology</i> , 2016, 127, 91-100.	2.4	69
68	Using Bundled Interventions to Reduce Surgical Site Infection After Major Gynecologic Cancer Surgery. <i>Obstetrics and Gynecology</i> , 2016, 127, 1135-1144.	2.4	95
69	Primary brain metastases of endometrial cancer: A report of 18 cases and review of the literature. <i>Gynecologic Oncology</i> , 2016, 142, 70-75.	1.4	40
70	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	21.4	77
71	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	2.5	64
72	Enhanced Recovery Pathway in Gynecologic Surgery. <i>Obstetrics and Gynecology Clinics of North America</i> , 2016, 43, 551-573.	1.9	91

#	ARTICLE	IF	CITATIONS
73	Disparities in treatment and survival for women with endometrial cancer: A contemporary national cancer database registry analysis. <i>Gynecologic Oncology</i> , 2016, 143, 98-104.	1.4	60
74	Disparities in Surgical Care Among Women With Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2016, 128, 526-534.	2.4	38
75	Staging for low malignant potential ovarian tumors: a global perspective. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 153-168.e2.	1.3	15
76	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 311-316.	1.4	103
77	The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. <i>Gynecologic Oncology</i> , 2016, 140, 270-276.	1.4	38
78	Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. <i>Gynecologic Oncology</i> , 2016, 141, 95-100.	1.4	58
79	Incorporating robotic-assisted surgery for endometrial cancer staging: Analysis of morbidity and costs. <i>Gynecologic Oncology</i> , 2016, 141, 218-224.	1.4	75
80	Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. <i>Gynecologic Oncology</i> , 2016, 140, 394-399.	1.4	139
81	Abdominal Incision Injection of Liposomal Bupivacaine and Opioid Use After Laparotomy for Gynecologic Malignancies. <i>Obstetrics and Gynecology</i> , 2016, 128, 1009-1017.	2.4	45
82	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. <i>Scientific Reports</i> , 2015, 5, 17369.	3.3	35
83	Second-line dovitinib in metastatic endometrial cancer. <i>Lancet Oncology</i> , The, 2015, 16, 604-606.	10.7	2
84	Abdominopelvic inflammatory myofibroblastic tumor that metastasized to the vertebrae and liver: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2015, 12, 9-12.	0.6	7
85	Surgical site infection after primary surgery for epithelial ovarian cancer: Predictors and impact on survival. <i>Gynecologic Oncology</i> , 2015, 136, 278-284.	1.4	39
86	Robotic radical hysterectomy in early stage cervical cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2015, 138, 457-471.	1.4	161
87	Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 70-77.	1.4	40
88	Risk-adjusted outcomes in elderly endometrial cancer patients: Implications of the contrasting impact of age on progression-free and cause-specific survival. <i>Gynecologic Oncology</i> , 2015, 138, 133-140.	1.4	14
89	Microarray Analysis on Gene Regulation by Estrogen, Progesterone and Tamoxifen in Human Endometrial Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 5864-5885.	4.1	18
90	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	1.4	79

#	ARTICLE	IF	CITATIONS
91	Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. <i>Gynecologic Oncology</i> , 2015, 137, 245-251.	1.4	14
92	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.9	157
93	Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. <i>Oncotarget</i> , 2015, 6, 36354-36369.	1.8	58
94	Detection of circulating tumor cells in high-risk endometrial cancer. <i>Anticancer Research</i> , 2015, 35, 683-7.	1.1	17
95	Incisional Recurrences After Endometrial Cancer Surgery. <i>Anticancer Research</i> , 2015, 35, 6097-104.	1.1	9
96	Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	298
97	Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. <i>Cancer &amp; Metabolism</i> , 2014, 2, 13.	5.0	27
98	Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 133, 485-493.	1.4	64
99	Short-term outcomes after incontinent conduit for gynecologic cancer: Comparison of ileal, sigmoid, and transverse colon. <i>Gynecologic Oncology</i> , 2014, 133, 563-567.	1.4	4
100	Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: A histologic dichotomy. <i>Gynecologic Oncology</i> , 2014, 132, 578-584.	1.4	33
101	Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 132, 38-43.	1.4	160
102	Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 423-427.	1.4	97
103	Resident participation in laparoscopic hysterectomy: balancing education with safety. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 444-445.	1.3	3
104	Enhanced recovery pathways in gynecologic oncology. <i>Gynecologic Oncology</i> , 2014, 135, 586-594.	1.4	119
105	Improving oncologic outcomes for women with endometrial cancer: Realigning our sights. <i>Gynecologic Oncology</i> , 2014, 133, 370-374.	1.4	43
106	Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 71-76.	1.4	8
107	Enhanced Recovery in Gynecologic Surgery. <i>Obstetrics and Gynecology</i> , 2013, 122, 319-328.	2.4	240
108	Conservative Management of Atypical Hyperplasia and Grade I Endometrial Carcinoma: Review of the Literature and Presentation of a Series. <i>Journal of Gynecologic Surgery</i> , 2012, 28, 262-269.	0.1	9



#	ARTICLE	IF	CITATIONS
109	Factors Predictive of Postoperative Morbidity and Cost in Patients With Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2012, 120, 1419-1427.	2.4	51
110	Lymphadenectomy in endometrial cancer: when, not if. <i>Lancet, The</i> , 2010, 375, 1138-1140.	13.7	27
111	The role of pelvic and para-aortic lymph node dissection in the surgical treatment of endometrial cancer: a view from the USA. <i>The Obstetrician and Gynaecologist</i> , 2009, 11, 199-204.	0.4	5
112	Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. <i>Gynecologic Oncology</i> , 2008, 109, 303-307.	1.4	73
113	Extra-peritoneal laparoscopic para-aortic lymphadenectomy – A prospective cohort study of 293 patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2008, 111, 418-424.	1.4	70
114	Treatment of pulmonary recurrences in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 107, 242-247.	1.4	22
115	Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2767-2776.	4.1	135
116	Overexpression of the TGF- $\beta$ 2 antagonist Smad7 in endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 96, 368-373.	1.4	61
117	Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 96, 389-394.	1.4	16
118	Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. <i>Gynecologic Oncology</i> , 2005, 99, 126-134.	1.4	76
119	Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1113-1123.	1.3	55
120	The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. <i>Cancer</i> , 2004, 101, 346-352.	4.1	165
121	Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. <i>Gynecologic Oncology</i> , 2003, 91, 563-568.	1.4	24
122	Preparing for the unexpected: encountering gynecological problems when operating for colon cancer. <i>Journal of Surgical Education</i> , 2003, 60, 12-16.	0.7	1
123	Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 1167-1173.	1.3	12
124	A Learning Health System Approach to Hospital Quality Performance Benchmarking: The Composite Hospital Quality Index. <i>American Journal of Medical Quality</i> , 0, Publish Ahead of Print, .	0.5	1